Investors in Gilead Sciences, Inc. (NASDAQ:GILD) saw new options begin trading this week, for the November 22nd expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $73.34 moved to $73.88 on last trade day and at the end of the day closed at $73.64. Company price to sales ratio in past twelve months was calculated as 10.11 and price to cash ratio as 53.13. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 0.84%.
Ariad Pharmaceuticals (NASDAQ:ARIA)‘s stock had its “positive” rating reaffirmed by investment analysts at BMO Capital Markets in a note issued to investors on Wednesday, American Banking News.com reports. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares advanced 5.71% in last trading session and ended the day on $8.52. ARIA return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly performance is -51.26%.
Exelixis, Inc. (NASDAQ:EXEL) on Mar. 25 announced that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis, Inc. (NASDAQ:EXEL) shares moved up 3.67% in last trading session and was closed at $3.67, while trading in range of $3.58 – $3.72. Exelixis, Inc. (NASDAQ:EXEL) year to date (YTD) performance is -40.13%.
Biopharmaceutical Company, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), expects majority of its revenue for the year to come from its flagship drug, Belviq. This is despite the company reporting a wider than expected net loss of 11 cents for its fourth quarter of 2013 that fell short of consensus estimates of earnings of 15 cents. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) weekly performance is 8.43%. On last trading day company shares ended up $6.56. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is -1.93%. Analysts mean target price for the company is $7.83.
Leave a Reply